Print pageHome » Celsis Expands into Mass Spec and Ion Chromatography
Celsis Expands into Mass Spec and Ion Chromatography
PharmaManufacturing.com
03/31/2010
Chicago, Ill. – Celsis Analytical Services, a division of Celsis International, announced the company has expanded the analytical chemistry capabilities of its accredited cGMP labs to include Mass Spectrometry (LC-MS/MS) and Ion Chromatography, making it easier to analyze complex materials and compounds.
“With the availability of mass spectrometry and ion chromatography, Celsis has increased its commitment to provide cost-effective, outsourced CGMP-certified laboratory services,” said Marc Caira, director of business development, Celsis Analytical Services. “Now, suppliers and manufacturers in a wide variety of industries – including pharmaceutical, biotechnology and consumer goods – can address their specialized testing needs, while avoiding costly investments in additional lab space, personnel and equipment.”
LC-MS/MS Services
Referenced in several chapters of the US Pharmacopeia (USP), LC-MS/MS enables analysts to separate, quantify and identify elements in complex mixtures. The LC-MS/MS testing method works by using HPLC to first separate the compounds. The mass spectrometer (MS) filters the separation in order to detect and identify components. A second MS may be used to further refine identifications. Celsis has both the Sciex API 5000 tandem (triple) Quadrupole and the Micromass Quattro Ultima mass spectrometers. In addition to USP testing, the mass spectrometry equipment can be used for raw material characterization, impurity identification, quality control programs and more.
Ion Chromatography Capabilities
The Dionex ICS-3000 ion chromatographic (IC) system has conductivity, amperometry and UV detectors. The system not only determines inorganic action, cations and organic acids but also uses amperometric detection for accurate analysis of traditionally difficult-to-analyze materials. These powerful IC techniques fill the void between liquid chromatography and gas chromatography analysis. Additional methods and benefits include: low level ion analysis with suppressed ion chromatography; conductivity detection for compounds such as sulphate, phosphate and fluoride; and integrated pulsed amperometry that overcomes problematic analysis of non-soluble products of an oxidation or reduction.
Visit www.celsis.com for more information.
More News:
-
02/09/2012
Watchdog Fines Ernst & Young $2 million Over Medicis Pharma Corp. AuditsFrom Reuters.com
The watchdog board for corporate auditors on Wednesday said it has imposed a $2 million penalty, its largest fine ever, on accounting and consulting firm Ernst & Young LLP in a settlement involving past audits of Medicis Pharmaceutical Corp.
-
02/09/2012
FDA Issues Draft Guidance on Biosimilar Product Development
The U.S. Food and Drug Administration today issued three draft guidance documents on biosimilar product development to assist industry in developing such products in the United States.
-
02/08/2012
Biomedical Industry Loses Momentum in California, According to 2012 Report
Innovation slows as productivity in the Biomedical industry declines
-
02/02/2012
Pfizer Baby Boom? Pfizer's Official StatementFrom Pharmalot.com
About nine months from now, a new phenomenon may appear at a hospital near you: the Pfizer baby. Why? The drugmaker has taken the embarrassing step of recalling 1 million packets of birth control pills due to a packaging error. Hear EVP and CMO, Freda Lewis-Hall's read Pfizer's official statement.
-
02/02/2012
News: AstraZeneca To Cut 7,300 JobsFrom MarketWatch.com
Drug firm AstraZeneca on Thursday said it would cut approximately 7,300 jobs as part of an ongoing initiative to reduce costs and drive innovation.
-
02/01/2012
Pfizer Recalls 1 Million Birth Control Packs for Error That Could Cause Unintended PregnancyFrom WashingtonPost.com
Pfizer Inc. is recalling 1 million packets of birth control pills due to a packaging error that could raise the risk of an accidental pregnancy by leaving women with an inadequate dose. The problem affects 14 lots of Lo/Ovral-28 tablets and 14 lots of generic Norgestrel and Ethinyl Estradiol tablets. Both products are manufactured by Pfizer and marketed in the U.S. by Akrimax Rx Products under the Akrimax Pharmaceuticals brand.
-
01/26/2012
News: Abbott Labs Cuts 700 Manufacturing JobsFrom WashingtonPost.com
Medical device and drugmaker Abbott Laboratories said Wednesday it will lay off 700 employees as part of ongoing restructuring efforts. A company spokeswoman said most of the layoffs will affect employees who manufacture the company’s heart stents and diagnostic tests.
- 01/24/2012 ISPE Announces 2012 FOYA Winners
- 01/24/2012 Genzyme Gains Approval for Framingham Site, a Boost to Fabrazyme Production
-
01/19/2012
Big Pharma Execs May Wish They'd Never Heard Of Paula DeenFrom Forbes.com
Novo Nordisk has nabbed Paula Deen as a new spokeswoman to help raise awareness about type 2 diabetes. Many in the drug industry wish it weren’t so, but without major legal and regulatory changes, such matches between celebs and drug firms are as certain as the sun rising in the east.
- All news »
Get Connected Now!
- Featured White Papers
Sponsored Links
